ALKS Alkermes plc

21.08
-0.17  -1%
Previous Close 21.25
Open 21.23
Price To Book 3.11
Market Cap 3,320,568,967
Shares 157,522,247
Volume 160,013
Short Ratio
Av. Daily Volume 1,689,630
Stock charts supplied by TradingView

NewsSee all news

  1. Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference

    DUBLIN, Nov. 26, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on

  2. Alkermes Completes Acquisition of Rodin Therapeutics

    DUBLIN, Nov. 25, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that it has completed its previously announced acquisition of Rodin Therapeutics, Inc. (Rodin), a privately held biopharmaceutical company.

  3. Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder

    DUBLIN, Nov. 19, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ALKS 3831

  4. Alkermes to Acquire Rodin Therapeutics

    DUBLIN and BOSTON, Nov. 18, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) and Rodin Therapeutics, Inc. (Rodin) today announced that they have entered into a definitive agreement under which Alkermes will acquire Rodin,

  5. Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

    DUBLIN, Nov. 12, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that its corporate presentation will be webcast live at the Stifel 2019 Healthcare Conference on Tuesday, Nov. 19, 2019 at 1:15 p.m. ET

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA approval announced July 2, 2018.
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD)
Schizophrenia
NDA filing announced November 19, 2019.
ALKS 3831 - ENLIGHTEN-2
Schizophrenia, bipolar
CRL received March 15, 2010.
BYDUREON
Type 2 diabetes
Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Aristada
Schizophrenia
FDA Approval announced October 30, 2019.
Diroximel fumarate (BIIB098)
Multiple sclerosis (MS)
Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 6428
Opioid dependence
CRL announced February 1, 2019.
ALKS 5461
Major depressive disorder
Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 3831 - ENLIGHTEN-1
Schizophrenia
Phase 1/2 data at SITC November 2019 - 8/14 SD for monotherapy, 12/18 for combo (incl. 2 PRs).
ALKS 4230 ARTISTRY-1
Solid tumors
Phase 3 data released April 9, 2019 - primary endpoint met.
Aristada and Invega Sustenna
Schizophrenia
Phase 1 data presented at SITC November 8, 2019.
ALKS 4230 + Keytruda - ARTISTRY-2
Solid tumors
Phase 3 top-line data met primary endpoint - July 30, 2019.
Diroximel fumarate (BIIB098) - Head-to-head trial versus Tecfidera -
Relapsing Remitting Multiple Sclerosis (RRMS)
Phase 2 trial to be initiated 4Q 2019.
ALKS 4230 + Keytruda (ION-01)
Head and neck squamous cell cancer

Latest News

  1. Alkermes to Present at the Evercore ISI 2nd Annual HealthCONx Conference

    DUBLIN, Nov. 26, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that its Chief Executive Officer, Richard Pops, will participate in a fireside chat at the Evercore ISI 2nd Annual HealthCONx Conference on

  2. Alkermes Completes Acquisition of Rodin Therapeutics

    DUBLIN, Nov. 25, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that it has completed its previously announced acquisition of Rodin Therapeutics, Inc. (Rodin), a privately held biopharmaceutical company.

  3. Alkermes Submits New Drug Application to U.S. Food and Drug Administration for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder

    DUBLIN, Nov. 19, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of ALKS 3831

  4. Alkermes to Acquire Rodin Therapeutics

    DUBLIN and BOSTON, Nov. 18, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) and Rodin Therapeutics, Inc. (Rodin) today announced that they have entered into a definitive agreement under which Alkermes will acquire Rodin,

  5. Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences

    DUBLIN, Nov. 12, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that its corporate presentation will be webcast live at the Stifel 2019 Healthcare Conference on Tuesday, Nov. 19, 2019 at 1:15 p.m. ET

  6. Alkermes Announces Receipt of $150 Million Milestone Payment from Biogen Related to FDA Approval of VUMERITY™

    DUBLIN, Nov. 12, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the receipt of a $150 million milestone payment from Biogen triggered by the recent U.S. Food and Drug Administration (FDA) approval of

  7. Alkermes Announces New Data From ALKS 4230 Clinical Development Program at Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

    DUBLIN, Nov. 8, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today presented new data from the company's ARTISTRY clinical development program related to ALKS 4230 at the Society for Immunotherapy of Cancer's

  8. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™

  9. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™

  10. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™

  11. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Ireland, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™

  12. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Oct. 30, 2019 /PRNewswire/ -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel

  13. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Oct. 30, 2019 /PRNewswire/ -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel

  14. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Oct. 30, 2019 /PRNewswire/ -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel

  15. Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis

    CAMBRIDGE, Mass. and DUBLIN, Oct. 30, 2019 /PRNewswire/ -- Biogen Inc. (NASDAQ:BIIB) and Alkermes plc (NASDAQ:ALKS) today announced that the U.S. Food and Drug Administration (FDA) approved VUMERITY™ (diroximel

  16. Alkermes Announces Clinical Collaboration With Fred Hutchinson Cancer Research Center for Novel Immuno-Oncology Drug Candidate ALKS 4230

    DUBLIN, Oct. 21, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced that it has entered into a clinical research collaboration with Fred Hutchinson Cancer Research Center (Fred Hutch) for ALKS 4230,

  17. Alkermes Presents New Health Economics and Outcomes Research on Patients With Schizophrenia and Bipolar I Disorder at 2019 Psych Congress

    DUBLIN, Oct. 7, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the  presentation of new health economics and outcomes research at the 32nd Annual Psych Congress (Psych Congress), which took place Oct.

  18. Alkermes to Present at the Cantor Fitzgerald Global Healthcare Conference

    DUBLIN, Sept. 26, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) announced today that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on Thursday, Oct. 3, 2019 at

  19. Alkermes Announces the Appointment of Richard Gaynor, M.D. and Andy Wilson to its Board of Directors and the Retirement of Director Floyd Bloom, M.D.

    DUBLIN, Sept. 13, 2019 /PRNewswire/ -- Alkermes plc (NASDAQ:ALKS) today announced the appointment of two new independent directors, Richard Gaynor, M.D. and Frank Anders (Andy) Wilson, to the company's Board of